MDxHealth's (MDXH) "Sell (E+)" Rating Reaffirmed at Weiss Ratings

Key Points

• MDxHealth's stock has been restated with a "sell (e+)" rating by Weiss Ratings, while other analysts have given mixed ratings, with one "buy" rating and a consensus target price of $7.00.
• The company reported earnings per share of ($0.15), missing expectations, with a negative net margin of 34.98% and a negative return on equity of 374.98%.
• Institutional trading activity showed significant interest as several investors increased their holdings in MDxHealth, with Delta Investment Management growing its stake by 459.1%.

MDxHealth (NASDAQ:MDXH - Get Free Report)'s stock had its "sell (e+)" rating restated by stock analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other research analysts have also recently issued reports on MDXH. Craig Hallum started coverage on shares of MDxHealth in a report on Thursday, July 17th. They issued a "buy" rating and a $8.00 target price for the company. Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a research report on Saturday, August 30th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, MDxHealth presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.00.

MDxHealth Price Performance

Shares of MDxHealth stock opened at $4.52 on Wednesday. The firm has a market cap of $213.74 million, a PE ratio of -5.14 and a beta of 1.65. MDxHealth has a 12-month low of $1.35 and a 12-month high of $4.94. The company has a quick ratio of 1.22, a current ratio of 1.31 and a debt-to-equity ratio of 13.81. The company's fifty day simple moving average is $3.60 and its two-hundred day simple moving average is $2.51.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The company had revenue of $26.60 million for the quarter, compared to the consensus estimate of $26.60 million. MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. As a group, equities analysts expect that MDxHealth will post -1.15 EPS for the current year.

Institutional Trading of MDxHealth

Institutional investors have recently modified their holdings of the stock. Castleview Partners LLC acquired a new position in MDxHealth during the first quarter worth about $48,000. Delta Investment Management LLC grew its holdings in MDxHealth by 459.1% during the 1st quarter. Delta Investment Management LLC now owns 190,100 shares of the company's stock worth $270,000 after acquiring an additional 156,100 shares in the last quarter. FreeGulliver LLC acquired a new position in MDxHealth during the 2nd quarter worth approximately $273,000. Perkins Capital Management Inc. grew its holdings in MDxHealth by 20.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock worth $1,678,000 after acquiring an additional 198,000 shares in the last quarter. Finally, AWM Investment Company Inc. boosted its holdings in shares of MDxHealth by 10.6% in the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock valued at $7,414,000 after buying an additional 499,992 shares in the last quarter.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.